Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP8 known ✓ | P22894 | 1/20 | 0.43 |
| ▸ | PPARG known ✓ | P37231 | 1/20 | 0.41 |
| ▸ | ACE known ✓ | P12821 | 1/20 | 0.41 |
| ▸ | METAP2 | P50579 | 1/20 | 0.59 |
| ▸ | IDO1 | P14902 | 2/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.45 |
| ▸ | ELANE | P08246 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | PPARA | Q07869 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL7323488 | 1.00 | METAP2 (0.59) | METAP2IDO1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL7323491 | 0.98 | METAP2 (0.60) | METAP2IDO1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL2238552 | 0.98 | METAP2 (0.60) | METAP2IDO1NPC1RAB9ASMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL7317995 | 0.87 | METAP2 (0.46) | METAP2IDO1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL10519231 | 0.87 | ALDH1A1 (0.49) | METAP2IDO1NPC1RAB9ASMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL3119114 | 0.87 | METAP2 (0.51) | METAP2IDO1PPARGPPARAACE | |
| Hydrochloric Acid SCHEMBL2971264 | 0.87 | METAP2 (0.51) | METAP2IDO1PPARGPPARAACE | |
| Hydrochloric Acid SCHEMBL4141147 | 0.87 | METAP2 (0.51) | METAP2IDO1PPARGPPARAACE | |
| SCHEMBL7317999 | 0.85 | METAP2 (0.47) | METAP2NPC1RAB9ASMN1; SMN2PIN1 | |
| SCHEMBL4141148 | 0.85 | METAP2 (0.52) | METAP2IDO1PPARGPPARACYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3015488-B1 | PRODUCTION METHOD FOR POLYAMINO ACID | TAKEDA PHARMACEUTICALS CO (JP) | 2024-03-06 | — | — | EP | disclosed |
| US-10336864-B2 | Production method for poly(amino acid) | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2019-07-02 | — | — | US | disclosed |
| US-20180044472-A1 | PRODUCTION METHOD FOR POLY(AMINO ACID) | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2018-02-15 | — | — | US | disclosed |
| US-9815938-B2 | Production method for poly(amino acid) | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-11-14 | — | — | US | disclosed |
| US-20160177032-A1 | PRODUCTION METHOD FOR POLY(AMINO ACID) | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-06-23 | — | — | US | disclosed |
| EP-3015488-A1 | PRODUCTION METHOD FOR POLYAMINO ACID | Takeda Pharmaceutical Company Limited (JP) | 2016-05-04 | — | — | EP | disclosed |
| EP-2239268-A1 | Dipeptide derivatives | Novartis AG (CH) | 2010-10-13 | — | — | EP | disclosed |
| US-20060058242-A1 | Dipeptide derivatives | FINK CYNTHIA A | 2006-03-16 | — | — | US | disclosed |
| US-6992105-B2 | Dipeptide derivatives | NOVARTIS AG (CH) | 2006-01-31 | — | — | US | disclosed |
| US-20040235754-A1 | Dipeptide derivatives | NOVARTIS AG (CH) | 2004-11-25 | — | — | US | disclosed |
| US-4929641-A | DIURETICS, ANGIOTENSIN CONVERTING ENZYMES | SCHERING CORPORATION (US) | 1990-05-29 | — | — | US | disclosed |
| US-4818749-A | Carboxyalkyl dipeptides and medical use thereof in treating hypertension and congestive heart failure | SCHERING CORPORATION (US) | 1989-04-04 | — | — | US | disclosed |
| US-4808573-A | ANGIOTENSIN CONVERTING ENZYME INHIBITORS | SCHERING CORPORATION (US) | 1989-02-28 | — | — | US | disclosed |
| US-4801609-A | Mercapto-acylamino acid antihypertensives | SCHERING CORPORATION (US) | 1989-01-31 | — | — | US | disclosed |
| EP-0254032-A2 | Neutral metalloendopeptidase inhibitors in the treatment of hypertension | SCHERING CORPORATION (US) | 1988-01-27 | — | — | EP | disclosed |
| EP-0050800-B1 | CARBOXYALKYL DIPEPTIDES, PROCESSES FOR THEIR PRODUCTION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | SCHERING CORPORATION (US) | 1986-06-18 | — | — | EP | disclosed |
| EP-0088350-B1 | CARBOXYALKYL DIPEPTIDES, PROCESSES FOR THEIR PRODUCTION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | SCHERING CORPORATION (US) | 1985-02-20 | — | — | EP | disclosed |
| US-4431644-A | CARDIOVASCULAR DISORDERS; DIURETICS | SCHERING CORPORATION (US) | 1984-02-14 | — | — | US | disclosed |
| EP-0088350-A1 | Carboxyalkyl dipeptides, processes for their production and pharmaceutical compositions containing them | SCHERING CORPORATION (US) | 1983-09-14 | — | — | EP | disclosed |
| EP-0050800-A1 | Carboxyalkyl dipeptides, processes for their production and pharmaceutical compositions containing them | SCHERING CORPORATION (US) | 1982-05-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180044472-A1 | PRODUCTION METHOD FOR POLY(AMINO ACID) | PGA5, ENPEP, PARG | MMP8 4693/4885PPARG 187/4885ACE 1449/4885 |
| US-10336864-B2 | Production method for poly(amino acid) | PGA5, ENPEP, PARG | MMP8 4693/4885PPARG 187/4885ACE 1449/4885 |
| US-20060058242-A1 | Dipeptide derivatives | ANPEP, ECE2, ECE1 | MMP8 608/4885PPARG 4878/4885ACE 20/4885 |
| US-20160177032-A1 | PRODUCTION METHOD FOR POLY(AMINO ACID) | PGA5, ENPEP, PARG | MMP8 4693/4885PPARG 187/4885ACE 1449/4885 |
| US-20040235754-A1 | Dipeptide derivatives | ANPEP, ECE1, ECE2 | MMP8 422/4885PPARG 4882/4885ACE 16/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.